Implanted passive engineering mechanisms and methods for their use and manufacture
09925035 ยท 2018-03-27
Assignee
Inventors
- Ravi Balasubramanian (Corvallis, OR, US)
- Taymaz Homayouni (Corvallis, OR, US)
- Francisco Valero-Cuevas (La Crescenta, CA, US)
Cpc classification
A61F2220/0075
HUMAN NECESSITIES
International classification
Abstract
Implantable passive engineered mechanisms and a method for implanting such devices in a subject are described. The implantable passive engineered mechanism may be made of or comprise a biocompatible material and is appropriately sized for implantation in a subject. Exemplary implantable passive engineered mechanisms may be selected from a strut, a pulley, a lever, a compliant mechanism, a scissor lift, a tendon network, springs, planetary gears, rigid or soft hydraulics, a linkage system, a cam/clutch system, or combinations thereof. In some embodiments the system comprises plural inserts, such as pulleys, levers, and/or tendon networks. Plural inserts may be arranged hierarchically to distribute force differentially from an input to one or more outputs.
Claims
1. An implantable passive engineered mechanism, comprising a triangular insert having a first, second, and third vertices and first, second, and third sides, the first side having at least one aperture to receive sutures for coupling the first side to a tendon or tendons and the second side having at least one aperture to receive sutures for coupling the second side to a tendon or tendons.
2. A method, comprising using an implantable passive engineered mechanism according to claim 1.
3. The method according to claim 2 wherein the implantable passive engineered mechanism comprises a biocompatible implantable passive engineered mechanism.
4. The method of claim 2 wherein the implantable passive engineered mechanism comprises a polymeric material, a metal, an alloy, or combinations thereof.
5. An implantable passive engineered mechanism comprising at least one component configured to scale an input force or movement to at least one tendon or muscle coupled to the mechanism, the implantable passive engineered mechanism comprising a prosthetic soft tendon network for coupling to biological tendons, the soft tendon network having a first, second, and third side, and first, second, and third vertices, the first vertex being sutured to an input force and the second and third vertices being configured for anchoring to a bone and to output tendons.
6. The mechanism according to claim 5 comprising a biocompatible material.
7. The mechanism according to claim 5 wherein the implantable passive engineered mechanism comprises a polymeric material, a metal, an alloy, or combinations thereof.
8. The mechanism according claim 5 wherein the implantable passive engineered mechanism comprises a biocompatible material.
9. A method, comprising using an implantable passive engineered mechanism according to claim 5.
10. An implantable passive engineered mechanism comprising at least one component configured to scale an input force or movement to at least one tendon or muscle coupled to the mechanism, the implantable passive engineered mechanism comprising a pulley having a pulley body, a wheel rotatable about an axle, and a pulley cable wound about the wheel, the cable comprising a first end and a second end, wherein the first end of the pulley cable is effectively coupled to an input force, and the second end of the pulley cable and the pulley body are coupled to a bone.
11. A method, comprising using an implantable passive engineered mechanism according to claim 10.
12. An implantable passive engineered mechanism, comprising three levers arranged hierarchically, each lever having a first end and a second end, and wherein the first and second ends of the first lever are effectively coupled to the second and third levers, and the first and second ends of the second and third levers can be effectively coupled to output tendons, and wherein an input force is effectively coupled to the first lever at a position between the first and second end.
13. The mechanism according to claim 12 comprising a biocompatible material.
14. The mechanism according to claim 12 comprising a polymeric material, a metal, an alloy, or combinations thereof.
15. A method, comprising using an implantable passive engineered mechanism according to claim 12.
16. An implantable passive engineered mechanism, comprising a scissor mechanism having a first end and a second end and wherein the first end has a first portion configured for anchoring to a bone and a second portion configured to be received in a slot defined in a bone and wherein the second end has a first portion for coupling to an input force and the mechanism is configured to be effectively coupled to an output tendon at a position between the two ends.
17. The mechanism according to claim 16 comprising a biocompatible material.
18. The mechanism according to claim 16 comprising a polymeric material, a metal, an alloy, or combinations thereof.
19. A method, comprising using an implantable passive engineered mechanism according to claim 16.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
(42)
(43)
(44)
(45)
(46)
DETAILED DESCRIPTION
I. Introduction
(47) Passive engineered mechanisms may be implanted at any of various locations in a subject. For example, in some embodiments they are used for tendon-transfer surgery and in other embodiments in general orthopedic surgery, to improve the functional attachment of muscles to tendons and bones. Common locations for implantation include, but are not limited to: (1) the hand, wherein the four tendons of the fingers (the flexor digitorum profundus, FDP, tendons) are coupled to the extensor carpi radialis longus (ECRL), the muscle of the forearm; (2) the elbow, wherein the biceps brachii is coupled to the ulna or the radius; and (3) the knee, wherein tendons are used to couple the large muscles of the thigh, such as the vastus medialis, vastus intermedius, and vastus lateralis, to the patella.
II. Definitions
(48) The following explanations of terms and abbreviations are provided to better describe the present disclosure and to guide those of ordinary skill in the art and practice of the present disclosure.
(49) Unless explained otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. Other features of the disclosure are apparent from the detailed description and the claims.
(50) As used herein, comprising means including and the singular forms a or an or the include plural references unless the context clearly dictates otherwise.
(51) The term or refers to a single element of stated alternative elements or a combination of two or more elements, unless the context clearly indicates otherwise.
(52) In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:
(53) Biocompatible:
(54) A substantially non-toxic material in vivo that is not substantially rejected by the patient's physiological system (e.g., is nonantigenic). This can be gauged by the ability of a material to pass the biocompatibility tests set forth in International Standards Organization (ISO) Standard No. 10993 and/or the U.S. Pharmacopeia (USP) 23 and/or the U.S. Food and Drug Administration (FDA) blue book memorandum No. G95-1, entitled Use of International Standard ISO-10993, Biological Evaluation of Medical Devices Part-1: Evaluation and Testing. Typically, these tests measure a material's toxicity, infectivity, pyrogenicity, irritation potential, reactivity, hemolytic activity, carcinogenicity and/or immunogenicity. A biocompatible structure or material, when introduced into a majority of subjects, will not cause a significantly adverse reaction or response. Furthermore, biocompatibility can be affected by other contaminants such as prions, surfactants, oligonucleotides, and other agents or contaminants. The term biocompatible material refers to a material that does not cause toxic or injurious effects on a tissue, organ, or graft. Examples, without limitation, of biocompatible materials include: titanium, ultra-high molecular weight polyethylene, polyvinylidene fluoride, and elastomers.
(55) Coat:
(56) As used herein, coat, coating, coatings, and coated are forms of the same term referring to materials and process for making a material where a first substance or substrate surface is at least partially covered or associated with a second substance. The first and second substances may be, but are not required to be, different. Further, when a surface is coated as used herein, the coating may be effectuated by any chemical or mechanical bond or force, including linking agents. The coating need not be complete or cover the entire surface of the first substance to be coated. The coating may be complete as well (e.g., approximately covering the entire first surface). There can be multiple coatings and multiple substances within each coating. The coating may vary in thickness or the coating thickness may be substantially uniform. Coatings contemplated in accordance with the present disclosure include, but are not limited to, biocompatible coatings, medicated coatings, drug-eluting coatings, drugs or other compounds, pharmaceutically acceptable carriers and combinations thereof, or any other organic, inorganic or organic/inorganic hybrid materials. Examples of biocompatible coatings include, but are not limited to: polyurethane, phosphorylcholine, bovine submaxillary mucin coatings, covalently grafted non-fouling layers, or surface immobilized brushes of chemicals including but not limited to sulfobetaine.
(57) Subject:
(58) An animal or human subjected to a treatment, observation or experiment.
III. Descriptions of Implantable Mechanisms
(59) Disclosed herein are various embodiments of implantable passive engineered mechanisms. Disclosed embodiments are useful to, for example, improve the functional attachment of muscles to tendons and bones by modifying the transmission of forces and movement inside the body.
(60) Certain disclosed embodiments are force scaling implants that are used to connect a single input force to a single output force and to allow for the input force to be scaled up or down to create a stronger or weaker output force. The input force may be an active muscular or tendon force, or a passive input, for example tenodesis. In tenodesis the tendon can be anchored to a bone or other fixed structure such that the rotation of the joint distal to the anchor lengthens the path of the mechanism, producing a force.
(61)
(62) A second pulley system comprises pulleys 104 and 106. Pulleys 104 and 106 are anchored at 124, and are connected to tendon or muscle at 136 and to tendon or muscle at 126. Pulleys 104 and 106 increase input force 136 by 3/2 before output 126.
(63) The third exemplary pulley system comprises pulleys 108, 110, and 112. The illustrated three pulley system anchors in two places, 128 and 130. This illustrated pulley configuration allows the output force to exceed the input force by a factor of 3.
(64) The fourth pulley system comprises two pulleys 114 and 116. Pulleys 114 and 116 are each anchored on one side to the same bone 134. This illustrated configuration allows the output force to exceed the input force by a factor of 4.
(65) In some embodiments, a pulley would be used for knee-joint surgery.
(66)
(67)
(68)
(69)
(70)
(71) Certain illustrated embodiments are differential action implants that connect a single muscle to multiple tendons. This arrangement allows for improved preferential enhancement, scaling, and/or distribution of an input's force and movement across the tendons. Unlike force scaling mechanisms, differential action implants may not be anchored to a bone.
(72)
(73)
(74)
(75)
(76)
(77)
(78)
(79)
(80)
(81)
(82)
(83)
(84)
(85)
(86)
(87)
(88)
(89)
(90)
(91)
(92)
(93)
(94)
IV. Implantable Materials
(95) A. Materials
(96) In considering materials for implantable mechanisms biocompatibility, tensile strength, ability to remain inert, and resistance to fibrosis are useful characteristics to consider. Materials should not trigger inflammation or immune responses. Materials may be chosen based on one or all of the above considerations depending on what function they are serving.
(97) Polymers are large molecules comprised of smaller related subunits. Polymer architecture, chain length, and arrangement affect the properties of the polymer. Longer chain lengths increase impact resistance and strength. Tensile strength of polymers increases as polymer chain length and crosslinking increase. With respect to polymers, suitable candidates include polyalkylenes, such as polytheylene, particularly Ultra High Molecular Weight Polyethylene (UHMWPE), nylon, polyester/polyethylene terephthalate (PET) and elastomers. Particular examples include poly-paraphenylene terephthalate and combinations thereof.
(98) In some embodiments, the materials implanted in the body will be metals and alloys. Metals and metal alloys may be chosen based on some, all, or none of the above considerations. Likely candidates for metals and metal alloys include titanium, stainless steel (only for temporary implants, least corrosion resistant), tantalum, and combinations thereof.
(99) B. Coatings/Sheaths
(100) In some embodiments the implantable materials must be coated partially or substantially completely to facilitate biocompatibility. Materials may be selected to inhibit or reduce fibrosis and tissue ingrowth and to inhibit biological adsorption and interaction events. Particular examples include but are not limited to polyurethane, phosphorylcholine, bovine submaxillary mucin coatings, covalently grafted non-fouling layers, surface immobilized brushes of chemicals including, but not limited to, sulfobetaine, and combinations thereof. In some embodiments component surfaces may be modified with a covalently-grafted, non-fouling layer or with a surface-immobilized brush (short polymeric chains densely grafted to a surface) of chemicals including but not limited to sulfobetaine (SB).
(101) Accordingly, an exemplary list of suitable materials includes, but is not limited to, Ceramic materials, such as magnesium aluminate spinel (inert biocompatible ceramic); polymers, such as PEEK (polyetheretherketone), PEKK (poly(oxy-p-phenyleneisophthaloyl-phylene/oxy-p-phenyleneterephthaloyl-p-phenylene), carbon-reinforced polymer composites, polyester, PET, silicone, PTFE (polytetrafluoroethylene) or ePTFE (expanded PTFE), PUR (polyurethane), PFA (perfluoroalkoxy alkane), FEP (Fluorinated ethylene propylene), UHMWPE, polyesters, polyanhydrides, polyethylenes, polyorthoesters, polyphosphazenes, polyurethane, polycarbonate urethane, silicones, polyolefins, polyamides, polycaprolactams, polyimides, polyvinyl alcohols, acrylic polymers and copolymers, polyethers, cellulosics and any of their combinations in blends or as copolymers; silicone backbone-modified polycarbonate urethane; metals, such as titanium and tantalum; alloys, such as nickel titanium, cobalt chrome alloys, stainless steel, shape memory alloys, nickel cobalt, titanium niobium; minerals, such as tricalcium phosphate (TCP) (controls tissue response), pyrolitic carbon; and coatings, such as hydroxyapatite (HA) and PEG (polyethylene glycol).
(102) In some embodiments the implantable materials may be fully enclosed in a biocompatible sheath to prevent interference with the surrounding biological tissues.
V. Implanting Methods and Method for Making
(103) A. Implanting Methods
(104) The implantable passive engineered mechanisms may be implanted and secured by existing surgical means, including but not limited to sutures, bone screws, bone anchors, or weaving.
(105) As shown in
(106) As shown in
(107) As shown in
(108) In particular embodiments of the strut or insert mechanism, the input muscle may be sutured to two output tendons. The strut or insert will be positioned between and sutured to the output tendons. In embodiments implanted in the hand the ECRL muscle would be sutured to two of the FDP tendons, which would have the strut or insert positioned between and sutured to the FDP tendons.
(109) In some embodiments, wherein the mechanism is a tendon network implanted in the arm, the distal ends of the tendon network are anchored to the radius and the ulna using bone screws. The biological FDP tendons are then sutured to the artificial tendons at the distal end of the network and the ECRL muscle is sutured to the artificial tendons at the proximal end of the network.
(110) In particular embodiments of the soft parallel tendon mechanism or a passive spring mechanism, the mechanism is sutured on the proximal ends to the input muscle, and on the distal ends to the output tendons.
(111) B. Making Disclosed Embodiments
(112) In some embodiments, the implantable passive engineered mechanisms may be made using any method now known or hereafter developed as will be understood by a person of ordinary skill in the art by methods including, but not limited to, 3D printing, Computer Numerical Control (CNC) Milling and/or Shape Deposition Manufacturing (SDM).
VI. Examples
(113) The following examples are provided to illustrate certain particular features and/or embodiments. These examples should not be construed to limit the disclosure to the particular features or embodiments described.
Example 1
(114) This example demonstrates the differences in grasping ability between the current suture based tendon-transfer procedure for high-median ulnar palsy and the tendon-transfer procedures using implanted pulley and lever based passive mechanisms.
(115) Both the suture-based procedure and the implanted pulley-based tendon transfer procedures were conducted on six cadaver arms with mean age of 90.62 years. The cadavers were thawed for a minimum of 24 hours and had reached a steady-state temperature before the first procedure was conducted.
(116)
(117) In the suture-based procedure, the ECRL tendon was routed in between the ulna and radial bones and directly sutured to the four FDP tendons with an end-to-side technique. The ECRL tendon was cut from the muscle belly and attached to the linear servomechanism to produce tendon excursion.
(118) In the pulley-based procedure, the ECRL tendon was sutured to a cable attached to a proximal pulley. The ring and small finger FDP tendons were sutured to a cable wrapped around a distal pulley, while the index and long finger tendons were sutured to a cable wrapped around a second distal pulley. The heads of both distal pulleys were attached with a cable that was wrapped around the proximal pulley. The proximal pulley had a diameter of 20 mm and was 10 mm thick, weighing 4.6 g. The distal pulleys were 15 mm in diameter and 10 mm thick, weighing 3.7 g. The cables were made of pre-strained 0.86-mm nylon-coated stainless steel. The forearms were sewn closed after the pulley mechanism was in place.
(119) Synchronized data streams from the single-axis load cell, motion capture system, and linear servomechanism were collected using National Instruments Labview software. The experimenter commanded the servomechanism's excursion in steps of 1.8 mm. The total servomechanism travel never surpassed the ECRL's optimal fiber excursion length of 8.1 cm. The servomechanism actuation was continued until all the fingers made contact with the ball or a maximum of 150 N in actuation force was reached. The actuation force used was thus less than the ECRL's maximum force of 304 N.
(120) A. AnalysisActuation force
(121) To analyze the force required by the ECRL to grasp the sphere, the actuation force applied by the servomechanism was recorded at the point where all fingers made contact with the ball for each trial by the single-axis load cell. The actuator force measured for each procedure and subject were averaged across the trials, such that Fsi represented the mean actuator force for subject i for the suture-based procedure, and Fpi the mean actuator force for the subject i for the pulley-based procedure. In order to test if the pulley-based procedure enabled grasp creation at lower actuation forces statistical significance of the force data for each subject was tested with a one-sided paired t test between the procedures.
(122) In addition, the ratio R.sub.fi=(F.sub.pi/F.sub.xi) of the mean actuation forces between the two procedures was also computed for each subject i. The ratio of forces R.sub.fi was averaged across all subjects to compute R.sub.F.
(123) B. Analysis-Finger Movement During Grasping
(124) The finger movement during a trial was processed using the OptiTrack Motive motion capture software to create time history data of each of the joint angles for each finger. Each finger's movement during the grasping process was quantified as the sum of movement of all the joints (i=MCP+PIP+DIP). The digital videos were analyzed to visually determine the time that each finger contacted the ball, which defined the stages of the grasping process.
(125) This experiment quantifies the adaptability in finger movement during grasping as the relative movement of fingers that have contacted the object with respect to the movement of fingers that have not contacted the object. The goal was to show the improvement in grasping capability through the entire grasping process and not just the final grasping state. This is because the grasping process involves a staggered interaction between the fingers and the object and the grasp can fail at any point. With this goal, the grasping process during each trial was split into four phases based on the sequence of fingers making contact: phase 1, movement beginning to first finger contact; phase 2, period between first finger contact and second finger contact; phase 3, period between second contact and third contact; and phase 4, period between third finger contact and fourth finger contact (full contact).
(126)
(127) For each of the grasping phases, the summation of the change in joint angles, .sub.c, for the fingers that established contact and the fingers that had not established contact, .sub.nc, was computed for each phase. It was expected that (1) the sum of the change in joint angles after contact, .sub.c, would be lower for the pulley-based procedure when compared with the suture-based procedure, and (2) the sum of the change in joint angles after contact .sub.c would be less than the sum of the change in joint angles .sub.nc for the pulley based procedure. This would indicate two things: (1) less slip of the fingers on the object during the grasping process; and (2) better adaptability of the fingers to the objects shape during the grasping process. For the suture-based procedure, .sub.c is expected to be equal to .sub.nc, showing coupled finger movement through the grasping process. The movement of the fingers that have not yet contacted the ball .sub.nc was also compared for the suture-based procedure and pulley-based procedures in order to verify if the pulleys hindered finger movement. Statistical significance was determined with an independent sample t test based on the mean of the joint angle changes computed across all the trials and subjects.
(128) C. Results
(129) A total of 29 trials for the suture-based procedure and 32 trials for the pulley-based procedure were analyzed across all of the subjects. Trials were omitted if the motion capture data could not be trajectorized due to marker occlusion or the markers could not be individually distinguished. This is because the markers placed on the fingers can come very close to each other during the grasping process. Also, the force required to create a full grasp is much greater for the suture based procedure than the pulley based procedure.
(130)
(131) For the 32 trials for the pulley-based procedure, there were 73 phases during the grasping process between the time when finger(s) made contact on the object and the subsequent finger(s) made contact (compared to an expected 96 if all fingers touched at separate times). The 29 trials for the suture-based procedure had 55 phases during the grasping process (compared to 87 expected). The remaining phases could not be analyzed due to incomplete motion capture data.
(132) For the pulley-based procedure, the mean joint angle change for fingers that made contact (.sub.c=2.990.28 was significantly different (p value<0.001) from the mean joint angle change for fingers that did not make contact (.sub.nc=6.420.57). The suture-based procedure mean joint angle changes, .sub.c=6.220.66 and .sub.nc=6.140.75, were not significantly different from each other (p value 0.9). The mean values of .sub.c across all six subjects for the pulley-based procedure were significantly less in value<0.001) than the corresponding values for the suture-based procedure.
(133) A key aspect of the grasping process is that it is difficult to predict which finger will make first contact with the object and where on the object it will make contact due to uncertainty in hand position or object shape. A healthy person overcomes this uncertainty through control over individual finger flexion. However, this is a significant issue for a patient with impairments, since the subject may not have individual control of finger flexion and proper tactile or proprioceptive feedback. Furthermore, the patient may be re-learning to use their musculature after a tendon transfer surgery. Specifically, patients who undergo the suture-based procedure for restoring finger flexion following high median ulnar palsy have coupled finger movement. Thus, the fingers do not adapt individually to the object's shape during grasping, forcing the patient to perform awkward wrist and arm movements to create a secure grasp. This effect will be most prominent when grasping objects of irregular shape.
(134) The implanted pulleys in the new procedure address this problem by enabling the fingers to individually adapt to the object shape and close in on the object using 45% less actuation force than the force required following the suture-based procedure. The unused muscle force may be used to increase grip strength after the fingers close in on the object. For example, for the suture-based procedure, if the fingers make contact with the object in a staggered fashion (either due to the object shape or tendon tensioning error), then the muscle must stretch the tendons of the fingers that have already established contact with the object in order to close the fingers that have not yet made contact. This would require greater actuation force than normal finger flexion which would only work against the much lower joint stiffnesses. Two benefits of the reduced force requirement after the pulley-based procedure are that (1) it could increase the number of candidate donor muscles for the surgery, and (2) it would mitigate the effects of losing muscle strength that is typical in tendon transfer surgery.
(135) The pulley-based procedure also leads to significantly better finger movement in terms of enabling the fingers to individually wrap around the object even when actuated by just one muscle. This is quantified through four major comparisons between the pulley-based and suture-based procedures based on the movement of fingers before and after making contact with the object. First, for the pulley-based procedure, the mean joint angle change .sub.c for those fingers that make contact is significantly smaller than the mean joint angle change .sub.nc for the fingers that have not contacted the object. This comparison shows that following the pulley-based procedure, the fingers that made contact move much less than the fingers that have not yet made contact and that the grasp changes minimally after each stage of the grasping process. Second, the mean joint angle change before and after contact for the suture-based procedure is similar, showing that the fingers have coupled movement even after contact has been made. This implies that the fingers that have made contact slip on the object's surface at the same rate that the fingers that have not made contact close in on the object.
(136) Third, the mean joint angle change for those fingers that have made contact, .sub.c, across all six subjects is significantly less for the pulley-based procedure when compared with the suture-based procedure. This indicates that the fingers that made contact after the pulley-based procedure do not slip as much on the object as the fingers after the suture-based procedure. Specifically, the suture-based procedure would lead to more than 18 joint angle change in the first finger to make contact at the end of a three-stage grasping process, 12 for the second finger to make contact, and 6 for the second finger that makes contact. This would result in a significant difference between the initial and final grasps. In contrast, the pulley-based procedure would only lead to half of the joint angle change between the initial and final grasps. Fourth, finger movement before making contact with the object was similar for both the pulley-based and suture-based procedures. This indicates that the pulleys do not hinder finger movement.
(137) These promising results from cadaver studies establish that the pulley-based tendon transfer surgery improves hand function compared to the suture-based procedure. However, some challenges must be overcome before this procedure can be used clinically. First, in addition to fabricating the device using biocompatible materials such as titanium or ultra high molecular weight polyethylene (UHMWPE), the mechanism may have to be chemically coated to reduce fibrosis when implanted in vivo long-term. Second, the pulley-based procedure also depends on technology to make attachments between the biological tendon and the mechanism's artificial components. Third, the mechanism may have to be enclosed in a sheath of biocompatible material in order to reduce injury to surrounding tissue while the mechanism moves inside the forearm.
Example 2
(138) This example demonstrates two embodiments of implantable passive engineered mechanisms for hand tendon-transfer surgery (1) a tendon network; and (2) a moving lever mechanism.
(139) The tendon-network implant was added to the OpenSim upper-extremity model using a web of tendons similar in properties to biological tendon. The tendon network has an equilateral triangular structure in order to distribute the forces and movement from one input (a muscle) across two outputs equally. This equilateral triangle is 32 mm long on each side. The proximal end of the network is attached to the ECRL muscle while the distal ends are attached to the finger tendons. The artificial tendons are chosen to have the same stiffness properties similar to biological tendons (normalized resistance force F=1.6x.sup.21.4x0.2, where x is the tendon strain). The physical version of the tendon network will be constructed from Kevlar or polyvinylidene fluoride (PVDF), which have favorable biological compatibility and mechanical properties. Since the tendon network is not rigid, it is anchored to the forearm bones (the ulna and radius bones) in order to maintain structure. The three ends of the triangle are allowed to slide in a plane parallel to the bones and thus each have three degrees of freedom. The anchor points are anchored to bones. The same triangular structure can be hierarchically assembled to create differential action from one muscle across more than two tendons.
(140) The moving-lever mechanism was added to the basic OpenSim upper-extremity model in the form of a single rigid cylindrical element (these models may be designed in 3D modeling software such as AutoCAD or created inside OpenSim itself). The ECRL muscle was connected at the center of the cylinder and the FDP tendons were attached at the two ends of the cylinder. Offsetting the position of the ECRL attachment to either side of the center would create larger forces on the tendon on that side, thus enabling scaled distribution of forces between the fingers. The cylinder was provided three degrees of freedom to translate and rotate in the plane. One challenge with the lever mechanism is that it would have to be long for large muscle contractions. This is because the lever mechanism ceases to create differential action when it rotates beyond 80 degrees. Specifically, calculations show that the tendon of one finger could travel up to 2.5 cm with a 3 cm long lever after another finger is stopped due to contact during grasping.
(141) Since the ECRL's maximum excursion capability is 3.9 cm, the patient would have to sacrifice some finger flexion capability for having the ability to scale the force transferred to different fingers. Three models, a suture procedure model and the two implant models, were compared. In all three models, finger movement was created by setting the ECRL to have a linear-ramp-and-plateau activation profile (linear ramp over 3 seconds from 0 to 75% excitation, and then held at 75% for 3 seconds). Contact between the fingers and the target object during the grasping process was simulated by creating contact between the index fingertip and an external rigid constraint as soon as the index finger flexed. The fingertips were set to be stiff with static, dynamic, and viscous friction coefficients of 0.8, 0.75, and 0.01 in order to represent the physical interaction between the human fingertip and the objects for grasping. Finger movement was measured using the total flexion of all three flexion joints (MCP, PIP, and DIP) in the finger. The differential movement and fingertip force created by the muscle action across the index and middle fingers were measured in each simulation.
(142) A. Results
(143)
(144) Conversely, it was also observed that less muscle force was required to close the fingers to the same extent following the implant-based procedure. Thus, when establishing a multi-finger power grasp, the fingers would adapt better to the object's shape at lower actuation force following the implant-based procedure.
(145) While the above results show that the implant-based procedure improves finger adaptability during power grasps, the influence of the suture-based and implant-based procedures during index-thumb precision grasp was also analyzed. Specifically, the suture-based procedure enables the immediate creation of a precision grasp once the index finger makes contact with the object, since the movement of all the fingers ceases immediately after the index finger makes contact. Thus, the contact force established between the index finger and the object is expected to be large. In the case of the implant-based procedure, strong contact forces can be established only after the other fingers also close in. This marginally reduces the contact forces that may be established in the precision grasp following the implant-based surgery. However, the simulations showed that the fingertip force enabled by the implant-based procedure in pinch grasps is still comparable to the fingertip force of a healthy person (about 27.9 N). Thus, the implant-based procedure is able to create differential action between multiple fingers to improve power grasping capability, while also enabling sufficient strength in pinch grasps similar to that of a healthy individual.
Example 3
(146) This example demonstrates an embodiment of an implanted passive engineered pulley-based mechanism that is used in knee-joint surgery.
(147) In order to restore knee strength following knee-replacement surgery, a pulley mechanism could be implanted between the quadriceps and the patella. The pulley would scale the quadriceps force by about 200%, while sacrificing about 50% of the range of motion. Such partial loss of range of motion in the knee is acceptable, because only 105 degrees of movement is necessary for daily activities. The pulley was incorporated into the basic OpenSim lower-extremity model by inserting and attaching an additional tendon to the four quadriceps muscle heads, routing it through a via point on the patella, and then anchoring it to the femur bone. This routing acts as a pulley because the tendon is free to slide around the via point on the patella. In both models with and without the implant, knee joint movement was created by setting all four quadriceps muscles to have a linear-ramp-and-plateau activation profile (linear ramp over 3 seconds from 0 to 75% excitation, and then held at 75% for 3 seconds). The knee joint torque was estimated using the force in a virtual spring attached to the tibia. This spring was modeled in OpenSim using a tendon with the same force-length curve as biological tendons. The knee joint's initial position was 54 degrees, and the knee joint's change in angle was measured.
(148) A. Results
(149)
(150) The uniqueness of the proposed work is that the passive implants better utilize the patient's own musculature to provide significantly better clinical interventions and outcomes than the current practice.
Example 4
(151) This example demonstrates the ability to implant a triangular insert into a chicken cadaver foot.
Example 5
(152) This example demonstrates the ability to implant a section of artificial tendon into a rat cadaver's tail in preparation for an in vivo experiment to determine whether the implant will cause significant irritation to the surrounding tissue and thus cause fibrosis.
(153)
(154)
(155) In view of the many possible embodiments to which the principles of the disclosed invention may be applied, it should be recognized that the illustrated embodiments are only preferred examples of the invention and should not be taken as limiting the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.